The Technical AnalystExchange: STO Sector: Healthcare Industry: Biotechnology
Egetis Therapeutics AB Price, Forecast, Insider, Ratings, Fundamentals & Signals
3.09% SEK7.00
America/New_York / 17 mai 2024 @ 11:29
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 2 048.00 mill |
| EPS: | -1.300 |
| P/E: | -5.38 |
| Earnings Date: | May 03, 2024 |
| SharesOutstanding: | 292.57 mill |
| Avg Daily Volume: | 0.411 mill |
| RATING 2024-05-17 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -5.38 | sector: PE 19.76 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.01x |
| Company: PE -5.38 | industry: PE 491.84 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
SEK-1.716 (-124.52%) SEK-8.72 |
| Date: 2024-05-18 |
| Expected Trading Range (DAY) |
|---|
|
SEK 6.69 - 7.31 ( +/- 4.43%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | SEK7.00 (3.09% ) |
| Volume | 0.332 mill |
| Avg. Vol. | 0.411 mill |
| % of Avg. Vol | 80.75 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For EGTX.ST
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
EGTX.ST
Egetis Therapeutics AB (publ), a pharmaceutical drug development company, focuses on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment. Its products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of MCT8 deficiency, a rare inborn error of thyroid hormone signaling that is in phase IIb/III clinical trial. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is based in Stockholm, Sweden.